Vicente Soriano

Summary

Affiliation: Hospital Carlos III
Country: Spain

Publications

  1. ncbi Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:511-7. 2008
  2. ncbi Rilpivirine : a next-generation non-nucleoside analogue for the treatment of HIV infection
    José Vicente Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, 28029 Madrid, Spain 34 91 4532500 34 91 7336614
    Expert Opin Pharmacother 13:1007-14. 2012
  3. ncbi Pharmacogenetics of hepatitis C
    Vincent Soriano
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 67:523-9. 2012
  4. ncbi Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
    Dimitrios Paraskevis
    Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
    Retrovirology 6:49. 2009
  5. ncbi Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
    Beatriz Larru
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    BMC Infect Dis 7:55. 2007
  6. ncbi Management of chronic hepatitis B and C in HIV-coinfected patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 57:815-8. 2006
  7. ncbi Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Infect Disord Drug Targets 6:57-88. 2006
  8. ncbi Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin
    Vincent Soriano
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 12:469-76. 2007
  9. ncbi Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, 28029, Spain
    J Infect Dis 195:1181-3. 2007
  10. ncbi Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    AIDS 21:1073-89. 2007

Detail Information

Publications144 found, 100 shown here

  1. ncbi Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:511-7. 2008
    ..Differences between PEG-IFN-alpha molecules could be more pronounced in HIV-coinfected individuals, in whom response to HCV treatment is impaired...
  2. ncbi Rilpivirine : a next-generation non-nucleoside analogue for the treatment of HIV infection
    José Vicente Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, 28029 Madrid, Spain 34 91 4532500 34 91 7336614
    Expert Opin Pharmacother 13:1007-14. 2012
    ..The availability of a fixed-dose coformulation of RPV with tenofovir/emtricitabine makes the use of RPV even more attractive. The efficacy of RPV in patients with a high baseline viral load remains to be clarified in further trials...
  3. ncbi Pharmacogenetics of hepatitis C
    Vincent Soriano
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 67:523-9. 2012
    ....
  4. ncbi Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
    Dimitrios Paraskevis
    Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
    Retrovirology 6:49. 2009
    ..However the spatial diffusion of the epidemic from the perspective of the virus has not previously been traced...
  5. ncbi Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
    Beatriz Larru
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    BMC Infect Dis 7:55. 2007
    ..The impact of HIV drug resistance mutations in salvage therapy has been widely investigated in adults. By contrast, data available of predictive value of resistance mutations in pediatric population is scarce...
  6. ncbi Management of chronic hepatitis B and C in HIV-coinfected patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 57:815-8. 2006
    ..Several guidelines have recently been released in response to this demand. In this article, we discuss the most critical issues highlighted in these documents...
  7. ncbi Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Infect Disord Drug Targets 6:57-88. 2006
    ..The relatively low efficacy of current anti-HCV medications and their low tolerability clearly indicated the need for new drugs with more potent and direct antiviral activity against HCV...
  8. ncbi Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin
    Vincent Soriano
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 12:469-76. 2007
    ..Chronic hepatitis C therapy in HIV patients is often penalized by more frequent premature treatment discontinuations. It is unclear what the relative contribution of more adverse events and/or early virological failures are...
  9. ncbi Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, 28029, Spain
    J Infect Dis 195:1181-3. 2007
    ..This information has important pathogenic implications and may influence therapeutic decisions...
  10. ncbi Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    AIDS 21:1073-89. 2007
  11. ncbi Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, C Sinesio Delgado, 10, 28029 Madrid, Spain
    J Hepatol 44:S44-8. 2006
    ....
  12. ncbi Complications in treating chronic hepatitis B in patients with HIV
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Expert Opin Pharmacother 6:2831-42. 2005
    ..Although response to IFN-alpha is poorer in HBV/HIV-coinfected patients compared with HBV-monoinfected individuals, the more potent pegylated forms of IFN-alpha have brought new hopes...
  13. ncbi New paradigms in the management of HIV and hepatitis C virus coinfection
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Curr Opin Infect Dis 18:550-60. 2005
    ..The bidirectional interferences between hepatitis C virus and HIV have clinical consequences and complicate the management of coinfected individuals...
  14. ncbi Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 192:1245-8. 2005
    ..Coinfection with distinct HCV genotypes is unlikely in former IDUs coinfected with HIV and does not explain the lower efficacy of HCV therapy in this population...
  15. ncbi Prevalence of drug resistance mutations in Spain among both naive and pretreated patients
    V Soriano
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    Antivir Ther 4:57-63. 1999
    ..Two major studies, one in 1997 and another in 1998, have been conducted so far. Global data and results derived from substudies are summarized in this presentation...
  16. ncbi Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 10:167-70. 2005
    ..HCV genotype 4 is spreading among European intravenous drug users, who are frequently coinfected with HIV. Information about treatment response in this subset of patients is scarce and conflicting results have been reported...
  17. ncbi Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    AIDS 19:221-40. 2005
  18. ncbi Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos II, Madrid, Spain
    Antivir Ther 9:987-92. 2004
    ..However, the occurrence of liver complications (including hepatocellular carcinoma) and/or HCV relapses in coinfected patients when followed for long periods of time after HCV therapy is not well known...
  19. ncbi Treatment failure with new hepatitis C drugs
    Vincent Soriano
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Pharmacother 13:313-23. 2012
    ..In the meantime, a wise use of DAA is warranted, including adequate selection of candidates for therapy, close monitoring of drug adherence, proper management of side effects and early application of stopping rules...
  20. ncbi Update on the treatment of chronic hepatitis C in HIV-infected patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Rev 9:99-113. 2007
    ..g. tenofovir, lamivudine, or emtricitabine). Didanosine should never be coadministered with ribavirin due to potential life-threatening complications...
  21. ncbi Hepatitis delta in HIV-infected individuals in Europe
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 25:1987-92. 2011
    ..There is scarce information about the prevalence, epidemiology, virological profile and natural history of hepatitis delta in HIV patients...
  22. ncbi Directly acting antivirals against hepatitis C virus
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 66:1673-86. 2011
    ..The complexity of HCV therapeutics has reached a point that presumably will lead to the birth of a new specialist, the HCV doctor...
  23. ncbi Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial
    Vicente Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 16:339-48. 2011
    ..Selection of first-line antiretroviral therapy requires consideration of efficacy as well as effects on lipids given the increased concern about cardiovascular risk in HIV-1 patients...
  24. ncbi Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:548-55. 2010
    ..Information about factors determining HBV genotype distribution and viraemia in HIV/HBV-co-infected patients is scarce...
  25. ncbi Viral hepatitis and HIV co-infection
    Vincent Soriano
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    Antiviral Res 85:303-15. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010...
  26. ncbi [Pharmacokinetics, interactions and mechanism of action of maraviroc]
    Vicente Soriano
    Departamento de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:12-6. 2008
    ..In addition, MVC dose adjustments are advised in patients with renal failure (CLcr <80 ml/min) only if they receive CYP3A4 inhibitors...
  27. ncbi New therapies for hepatitis C virus infection
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 48:313-20. 2009
    ..Herein, the main characteristics of these new antiviral agents and the most important challenges arising with their use--namely, toxicities and rapid selection of resistance--are discussed...
  28. ncbi Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 198:1337-44. 2008
    ....
  29. ncbi Management of hepatitis B virus co-infection on and off antiretroviral therapy
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Curr HIV/AIDS Rep 5:86-93. 2008
    ..Hopefully, this success will translate into a halt of liver-related complications and death in the co-infected population...
  30. ncbi Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 62:1-4. 2008
    ....
  31. ncbi Emerging drugs for hepatitis C
    Vincent Soriano
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Emerg Drugs 13:1-19. 2008
    ....
  32. ncbi Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 61:200-5. 2008
    ..If proved, this strategy could be particularly attractive for the subset of patients with greater cardiovascular risk...
  33. ncbi Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 9:505-9. 2004
    ..Therefore, extending therapy (for 12 months in HCV genotypes 2/3 and perhaps for 18 months in HCV genotypes 1/4) might be warranted in HIV/HCV-coinfected patients showing EVR...
  34. ncbi Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users
    V Soriano
    Service of Infectious Diseases, Centro de Investigaciones Clinicas, Instituto de Salud Carlos III, Madrid, Spain
    Eur J Epidemiol 15:1-4. 1999
    ..In conclusion, CVLD represents an important cause of hospital admission and death in HIV-infected drug users...
  35. ncbi Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations
    V Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Viral Hepat 11:2-17. 2004
    ..These guidelines represent a comprehensive and updated overview on the management of hepatitis B and C in HIV-infected patients...
  36. ncbi Genetic mechanisms of resistance to protease inhibitors and entry inhibitors
    Vincent Soriano
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:249-57. 2002
    ..In contrast, agents that target gp41-dependent fusion select for HIV variants with mutations in the gp41 envelope gene...
  37. ncbi Genetic mechanisms of resistance to NRTI and NNRTI
    Vincent Soriano
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:237-48. 2002
    ..In respect to nonnucleoside reverse transcriptase inhibitors (NNRTIs), resistance often results from single mutations (K103N is the most frequently found) located at or near the drug pocket binding...
  38. ncbi Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J HIV Ther 14:13-8. 2009
    ..At this time, most experts agree that early introduction of anti-HBV active HAART is the best strategy for the treatment of chronic hepatitis B in HIV patients, and Truvada must be part of the triple regimen...
  39. ncbi Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients
    Vincent Soriano
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 20:351-3. 2004
    ..8% for HCV genotypes 1-4) and/or the use of either standard or pegylated IFN (37% versus 29%, respectively). Thus, extended periods of anti-HCV therapy might reduce HCV relapses in HIV-coinfected patients initially responding to therapy...
  40. ncbi Hepatitis C and HIV infection: biological, clinical, and therapeutic implications
    V Soriano
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III Madrid, Spain
    J Hepatol 31:119-23. 1999
    ....
  41. ncbi Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load
    V Soriano
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    J Med Virol 61:111-6. 2000
    ..A lower cellular and plasma viral load with respect to HIV-1 was seen in persons without immunosuppression, from whom the rate of virus recovery was extremely low...
  42. ncbi [Role of tenofovir in HIV and hepatitis C virus coinfection]
    Paula Tuma
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:31-7. 2008
    ..Tenofovir is currently one of the safest nucleos(t)ide analogues, due to its low hepatotoxicity and its lack of negative interference on treatment of HCV infection...
  43. ncbi Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients
    Pablo Labarga
    Department of Infectious Diseases, Hospital Carlos III, Madrid 28029, Spain
    J Infect Dis 196:670-6. 2007
    ..It is unknown whether sustained HCV clearance after interferon (IFN)-based therapy might reduce this complication...
  44. ncbi [Human immunodeficiency virus infection and viral hepatitis]
    Vicente Soriano
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 29:691-701. 2011
    ..However, interactions between these drugs and antiretroviral agents and the risk of selective resistance pose huge threats in this population...
  45. ncbi Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 26:419-24. 2010
    ..Extensive intraerythrocyte accumulation of RBV following boosted production of red blood cells by EPO could explain these findings...
  46. ncbi Prevalence of and risk factors for hepatitis B virus infection among street-recruited young injection and non-injection heroin users in Barcelona, Madrid and Seville
    Fernando Vallejo
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Espana
    Eur Addict Res 14:116-24. 2008
    ..To evaluate the prevalence of hepatitis B virus (HBV) and associated factors in 949 heroin users (HU): injectors (IHUs) and non-injectors (NIHUs)...
  47. ncbi HIV protease inhibitors: recent clinical trials and recommendations on use
    José Vicente Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, Madrid, Spain
    Expert Opin Pharmacother 10:1615-29. 2009
    ..PIs have evolved over the years to gain in potency, convenience, tolerability and genetic barrier to resistance...
  48. ncbi [Advances in the diagnosis and treatment of the infection by the hepatitis B virus]
    Marina Nunez
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Spain
    Enferm Infecc Microbiol Clin 22:539-49. 2004
    ..While the selection of lamivudine resistance mutations is frequent, adefovir has a high genetic barrier. HIV infection negatively impacts on HBV disease, requiring these coinfected patients strategies aimed to manage both viruses...
  49. ncbi Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy "don't ask, draw a blood sample, vaccinate and try to schedule another visit"
    Luis de la Fuente
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, C Sinesio Delgado 6, 28029 Madrid, Spain
    J Clin Virol 38:87-90. 2007
    ..To assess the validity of self-reported hepatitis B virus vaccination status in young heroin users...
  50. ncbi [Resistance in hepatitis B virus]
    Julie Sheldon
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:49-55. 2008
    ..The characterization of the resistance mutations is helpful for the prevention and the optimization of antiviral therapies...
  51. ncbi Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens
    Luisa Valer
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Patient Care STDS 18:1-6. 2004
    ..In summary, HIV genotyping but not drug levels might be helpful to predict which patients would benefit from a rescue intervention based on APV/RTV 600/100 twice daily...
  52. ncbi Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:429-37. 2008
    ..There is little information about the influence of antiretroviral drugs on the antiviral activity of pegylated interferon (PEG-IFN) plus ribavirin (RBV) against hepatitis C virus (HCV)...
  53. ncbi Hepatitis B vaccination: an unmet challenge in the era of harm reduction programs
    Fernando Vallejo
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
    J Subst Abuse Treat 34:398-406. 2008
    ..The proportion of vaccinated HUs remains very low despite efforts to set up harm reduction programs. New and more active strategies must be incorporated in these programs...
  54. ncbi HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates
    Luis de la Fuente
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, C Sinesio Delgado 6, 28029 Madrid, Spain
    J Clin Virol 35:244-9. 2006
    ....
  55. ncbi Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program
    M Jesús Pérez-Elías
    Hospital Ramon y Cajal, Madrid, Spain
    Enferm Infecc Microbiol Clin 27:28-32. 2009
    ..The objective of this study was to collect safety data on treatment with fosamprenavir/ritonavir (FPV/r) 700/100mg BID in HIV-infected patients through an expanded access program...
  56. ncbi Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:842-8. 2006
    ..Thus, HBV/HIV-coinfected patients might benefit from an earlier introduction of HAART...
  57. ncbi Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C
    Luz Martin-Carbonero
    Hospital Carlos III, CIBERehd, Madrid, Spain
    AIDS 22:15-21. 2008
    ..It is unclear whether this applies to HIV/HCV-co-infected patients...
  58. ncbi [Viral resistance and genetic barrier of atazanavir]
    Carmen de Mendoza
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:28-33. 2008
    ..Despite having a moderate genetic barrier when not boosted with ritonavir, the prolonged half life of ATV minimises the risk of resistance in clinical practice...
  59. ncbi Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes
    Luis de la Fuente
    Centro Nacional de Epidemiologia, Instituto, de Salud Carlos III, Madrid, C Sinesio Delgado 6, 28029 Madrid, Spain
    J Epidemiol Community Health 60:537-42. 2006
    ..To evaluate changes in the prevalence of HIV infection among young heroin users in three Spanish cities, and their association with harm reduction programmes (HRPs)...
  60. ncbi The role of injection versus socioeconomic factors in hepatitis A virus infection among young heroin users: Implications for vaccination policies
    Francisco J Luquero
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain European Programme for Intervention Epidemiology Training EPIET, European Centre for Disease Prevention and Control ECDC, Stockholm, Sweden
    Vaccine 27:2674-9. 2009
    ..Consequently, HAV vaccination should be recommended not only in IDUs but also in non-IDUs depending on their socioeconomic characteristics...
  61. ncbi Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations
    Miriam Romero
    Gastroenterology and Hepatology Department, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    Drug Saf 27:7-24. 2004
    ..New IFN formulations (e.g. pegylated interferon) plus ribavirin appear to be way of the future for the treatment of chronic hepatitis C in patients both with and without HIV co-infection...
  62. ncbi Liver complications have reached a plateau as cause of hospital admission and death in HIV patients in Madrid
    Carla Núñez-Fernández
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 25:383-5. 2009
    ..Hepatic complications are currently still responsible for 8.7% of all hospital admissions and one-third of in-hospital deaths, with hepatitis C virus infection by far the leading etiologic agent...
  63. ncbi Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients
    Marina Nunez
    Department of Infectious Diseases Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Acquir Immune Defic Syndr 45:439-44. 2007
    ..Relapse after achieving virologic response to anti-hepatitis C virus (HCV) treatment considerably reduces sustained virologic response rates. It is unclear what the main predictors of relapse in HCV/HIV-coinfected patients are...
  64. ncbi Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center
    Ivana Maida
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 6:329-36. 2005
    ..CONCLUSION: More flexible criteria would considerably increase the number of patients to be treated with IFN-based therapy. The majority of patients ready to initiate HCV therapy have a poor therapeutic profile...
  65. ncbi [Diagnosis of HIV-1 non-B subtypes and HIV-2]
    Carlos Toro
    Servicio de Microbiologia, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:66-70. 2008
    ..The availability of both in vitro and clinical data from studies of HIV-1 non-B subtypes will improve the performance of bioinformatics tools...
  66. ncbi Treatment of chronic hepatitis B in HIV-infected patients in 2007
    Pilar Garcia-Gasco
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    J HIV Ther 12:19-23. 2007
  67. ncbi Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C
    Judit Morello
    Laboratory of Pharmacology, Hospital Carlos III, 28029 Madrid, Spain
    Antimicrob Agents Chemother 54:1647-9. 2010
    ..5 microg/ml (4.5 [1.3 to 15.5]), baseline serum HCV RNA (2.5 [1.2 to 5.1]), and HCV genotype 1 or 4 (13.3 [2.6 to 66.7]). Monitoring of RBV C(trough) may permit early adjustment of RBV dosage to avoid HCV relapse...
  68. ncbi Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    AIDS Res Hum Retroviruses 23:972-82. 2007
    ..The use of RBV 1000-1200 mg/day plus pegIFN is relatively safe and provides SVR in nearly half of coinfected patients, twice as high in HCV-2/3 than HCV-1/4...
  69. ncbi Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients
    Luz Martin-Carbonero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:1231-5. 2006
    ..The presence of TAMs precluded the selection of K65R in patients treated with TDF. Resistance pathways for TDF and thymidine analogues seem to be divergent and could be the basis to explore a synergism between these drugs...
  70. ncbi Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection
    Judit Morello
    Laboratory of Pharmacology, Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 202:1185-91. 2010
    ....
  71. ncbi Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 7:163-71. 2006
    ..The efficacy is greatly influenced by the number of baseline protease resistance mutations; 5 mutations is the best threshold to predict the chances of VR to any PI/r-based regimen...
  72. ncbi Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals
    Oscar Gallego
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Virol Methods 121:115-8. 2004
    ..The inclusion of additional sequences in the VircoNET database, mainly those derived from heavily treatment-experienced patients and/or from patients failing the most recently approved drugs might improve its performance...
  73. ncbi Predictors of virological response to atazanavir in protease inhibitor-experienced patients
    Ana Barrios
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 5:201-5. 2004
    ..The GIQ predicts accurately the virological response in patients receiving ATV. Hyperbilirubinemia is associated with higher ATV plasma levels...
  74. ncbi Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort
    Juan Berenguer
    Infectious Diseases and HIV Unit, Hospital Gregorio Maranon, Madrid, Spain
    J Acquir Immune Defic Syndr 41:154-9. 2006
    ..To analyze the safety and effectiveness of abacavir, lamivudine, and zidovudine (ABC/3TC/ZDV) in antiretroviral therapy (ART)-naive HIV-infected patients...
  75. ncbi Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000
    Javier Garcia-Samaniego
    Hepatology, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:99-114. 2002
    ..The role of orthotopic liver transplantation for co-infected individuals with end-stage liver disease was also assessed...
  76. ncbi [Adaptive cell immune response against the hepatitis C virus infection]
    Norma Ibón Rallón
    Laboratorio de Biologia Molecular, Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Med Clin (Barc) 129:469-76. 2007
    ..An integral interpretation of the numerous experimental findings may allow a better understanding of the immune mechanisms involved in the inability of the immune system to successfully control chronic HCV infection...
  77. ncbi [Recruitment methodology and characteristics of a cohort of young regular cocaine users in three Spanish cities (the Itinere-cocaine Project)]
    Jose Pulido
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Espana
    Gac Sanit 23:200-7. 2009
    ..We describe the recruitment methodology and characteristics of a cohort of young cocaine users...
  78. ncbi Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS 22:2535-7. 2008
    ..A substantial proportion of patients under atazanavir-therapy experienced significant hyperbilirubinemia and jaundice following initiation of hepatitis-C therapy...
  79. ncbi Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 24:821-5. 2008
    ..Patients with complete viral suppression under ATV/r 300/100 mg qd may benefit from switching to ATV 400 mg qd guided by TDM, which may make it possible to minimize adverse events without compromising antiviral efficacy in most cases...
  80. ncbi Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients
    Luisa Valer
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Med Virol 77:460-4. 2005
    ..At any time, nevertheless, the GIQ provided the most accurate prediction of the VR...
  81. ncbi Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1
    Sonia Rodriguez Novoa
    Clinical Pharmacokinetic Unit, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 42:291-5. 2006
    ..Plasma levels of atazanavir were significantly higher in patients with genotype CC than in those with CT or TT, and bilirubin levels correlated with atazanavir concentrations...
  82. ncbi Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 21:583-8. 2007
    ..Information on the impact of therapy with pegylated interferon (pegIFN) plus ribavirin on mtDNA is scarce and conflicting results have been reported...
  83. ncbi Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse
    Pablo Labarga
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    J Acquir Immune Defic Syndr 53:364-8. 2010
    ....
  84. ncbi Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir
    Julie Sheldon
    Hospital Carlos Ill, Madrid, Spain
    Antivir Ther 10:727-34. 2005
    ..In vitro, rtA194T conferred a reduced susceptibility to TDF in the presence of LAM-associated mutations...
  85. ncbi [Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]
    Ana María Caro-Murillo
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
    Enferm Infecc Microbiol Clin 25:23-31. 2007
    ..To describe the methodology and baseline results of the Spanish cohort of naïve HIV-infected patients included in the Research Network on HIV/AIDS (CoRIS)...
  86. ncbi High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement
    Eduardo Seclen
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Clin Microbiol 49:3380-2. 2011
    ..Disagreement was found mostly in specimens with short V3 lengths (<35 amino acids). Thus, consideration of V3 lengths should improve the predictability of HIV-1 tropism using genotypic algorithms...
  87. ncbi Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families
    Carmen de Mendoza
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:304-9. 2002
    ..Genotyping at the time of initiation of salvage therapy with Kaletra might help to predict which individuals will experience a greater benefit...
  88. ncbi Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir
    Julie A Sheldon
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 19:2036-8. 2005
    ....
  89. ncbi Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption
    Pablo Barreiro
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 41:897-900. 2005
    ..001). Distinct pharmacokinetics and resistance barriers may result in different performances for PIs and NNRTIs after treatment interruptions...
  90. ncbi Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection
    Carmen de Mendoza
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Med Virol 76:1-6. 2005
    ..Thus, keeping on treatment HIV-infected individuals failing virologically and harboring drug-resistant viruses may ameliorate their immunological deterioration until new drugs became available...
  91. ncbi Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia
    Eduardo Seclen
    Laboratory of Molecular Biology, Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:1493-6. 2010
    ..In this context, information on tropism might be obtained from testing either older stored viraemic sera collected before initiation of ART or current proviral DNA in peripheral blood cells...